Yesterday, the FDA approved a generic EpiPen made by Teva Pharmaceuticals, injecting much needed competition into the market and opening a new chapter in a saga that began nearly two years ago with the revelation that EpiPen prices had been raised over 500% in less than a decade.
That scandal turned the tide of public opinion against Mylan, the company that manufactures EpiPens, which became synonymous with pharmaceutical greed. Mylan's CEO, Heather Bresch, was dragged before congressional hearings and forced to explain the rationale behind such 'unconscionable' pricing.
